News
NCATS Awards $12.7M for Nine Drug Repurposing Projects
NIH’s National Center for Advancing Translational Sciences (NCATS) awarded a total $12.7 million to nine academic research groups toward repurposing seven of 58 compounds made available by pharma giants through the agency-industry Discovering New Therapeutic Uses for Existing Molecules pilot program. Saracatinib (AZD0530), an Src tyrosine kinase inhibitor, will be explored as a potential Alzheimer’s therapy by Yale University researchers Stephen M. Strittmatter, M.D., Ph.D., Haakon Berge Nygaar
Source: Genetic Engineering & Biotechnology News